PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome.

作者: Sathibalan Ponniah , Ifeyinwa Arah , Richard B. Alexander

DOI: 10.1002/1097-0045(20000615)44:1<49::AID-PROS7>3.0.CO;2-7

关键词:

摘要: BACKGROUND Previous studies demonstrated that recognition of seminal plasma antigens can occur in patients with chronic prostatitis/chronic pelvic pain syndrome. This suggests an autoimmune component may contribute to symptoms some men. To determine if any the principal secretory proteins prostate could be candidate prostatitis, we examined recall proliferative response purified CD4 T cells prostatitis and normal volunteers using autologous dendritic cells. METHODS Peripheral blood mononuclear were harvested from 14 12 by density gradient centrifugation. The stimulating irradiated produced culture monocyte-enriched fractions IL-4 Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). Purified responding population. Recall proliferation assays performed, as antigens. RESULTS In detected a greater than 2-fold increase PSA compared control 5 (36%). No Prostatic Acid Phosphatase (PAP) or β-microseminoprotein was observed these patients. In volunteer donors no history genitourinary disease symptoms, above background for prostatic antigen. CONCLUSIONS The data suggest men have evidence T-cell PSA. is antigen syndrome appropriate target immunotherapy cancer. Prostate 44:49–54, 2000. © 2000 Wiley-Liss, Inc.

参考文章(21)
L. G. Gomella, M. J. Mastrangelo, D. T. Harris, E. Talor, M. D. Winship, L. E. Spitler, G. R. Matyas, Immunologic approaches to the treatment of prostate cancer. Seminars in Oncology. ,vol. 26, pp. 439- 447 ,(1999)
D Brockstedt, E G Engleman, C L Ruegg, L Fong, R Laus, Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. Journal of Immunology. ,vol. 159, pp. 3113- 3117 ,(1997)
Jeffrey Schlom, Pierpaolo Correale, Sam Zaremba, MingZhu Zhu, Kwong Y. Tsang, Konstantin Walmsley, Generation of Human Cytolytic T Lymphocyte Lines Directed Against Prostate-Specific Antigen (PSA) Employing a PSA Oligoepitope Peptide Journal of Immunology. ,vol. 161, pp. 3186- 3194 ,(1998)
M A Cheever, K J Liu, G S Chatta, A G Spies, D R Twardzik, L D True, T S Vedvick, Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy. Journal of Immunology. ,vol. 159, pp. 472- 480 ,(1997)
Richard B Alexander, Francine Brady, Mary Sue Leffell, Van Tsai, Esteban Celis, Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. Urology. ,vol. 51, pp. 150- 157 ,(1998) , 10.1016/S0090-4295(97)00480-9
MARY McNAUGHTON COLLINS, RANDALL S. STAFFORD, MICHAEL P. O'LEARY, MICHAEL J. BARRY, How common is prostatitis? A national survey of physician visits. The Journal of Urology. ,vol. 159, pp. 1224- 1228 ,(1998) , 10.1016/S0022-5347(01)63564-X
H. Lilja, P.-A. Abrahamsson, Three predominant proteins secreted by the human prostate gland The Prostate. ,vol. 12, pp. 29- 38 ,(1988) , 10.1002/PROS.2990120105
James W. Hodge, Jeffrey Schlom, Susan J. Donohue, Joseph E. Tomaszewski, Clyde W. Wheeler, Barry S. Levine, Linda Gritz, Dennis Panicali, Judy A. Kantor, A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): Safety and immunogenicity in a non-human primate International Journal of Cancer. ,vol. 63, pp. 231- 237 ,(1995) , 10.1002/IJC.2910630215
E. Celis, V. Tsai, C. Crimi, R. DeMars, P. A. Wentworth, R. W. Chesnut, H. M. Grey, A. Sette, H. M. Serra, Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes Proceedings of the National Academy of Sciences of the United States of America. ,vol. 91, pp. 2105- 2109 ,(1994) , 10.1073/PNAS.91.6.2105
A N Houghton, Cancer antigens: immune recognition of self and altered self. Journal of Experimental Medicine. ,vol. 180, pp. 1- 4 ,(1994) , 10.1084/JEM.180.1.1